Skip to content
Psilocybin Technology
Menu
  • Home
  • Contact us about Psilocybin Science and Technology

Tag: research

Legalization / Molecules vs. Mushrooms / Research / Treatment

DEA Puts Anti-Epileptic CBD Drug on Schedule V

A Historic Decision by the DEA On September 27, 2018, the US Drug Enforcement Agency (DEA) announced it was placing the childhood epilepsy drug, Epidiolex, on schedule V of the …

Legalization / Psilocybin Science / Research

Johns Hopkins Scientists Recommend Rescheduling Psilocybin

Scientists at Johns Hopkins Medical School Recommend Rescheduling Psilocybin Since 1970, psilocybin has been categorized as a Schedule I drug by the U.S. Drug Enforcement Agency (DEA).  Schedule I is …

Molecules vs. Mushrooms / Psilocybin / Psilocybin Chemistry / Research / Treatment

Psilocybin Clinical Trials Approved by FDA

FDA Approves COMPASS Pathways’s Psilocybin Clinical Trials The United States Food and Drug Administration (FDA) has approved COMPASS Pathways’s clinical trials using psilocybin for treating depression, namely “Treatment Resistant Depression” …

Molecules vs. Mushrooms / Psilocybin / Psilocybin Chemistry / Psilocybin Derivatives / Research / State of the Art / Unmet Need

Magic Mushrooms vs Cannabis – Entourage Effect

Entourage Effect – Synergistic Combinations of Active Ingredients Magic mushrooms contain multiple active ingredients, collectively called “psilocybin derivatives.” These molecules work together to create an “entourage” of psychoactive (and non-psychoactive) effects …

Depression / Psilocybin / Research / Treatment / Unmet Need

COMPASS Pathways – Access to Synthetic Psilocybin

COMPASS Pathways Targeting “Patient Access” to Synthetic Psilocybin COMPASS Pathways is a life sciences company, founded in 2016, to “accelerate patient access to evidence-based innovation in mental health.” According to their …

Decriminalization / Law / Legalization

Psilocybin and the “Right to Try Act”

Psilocybin and the “Right to Try Act” On Wednesday, May 29th, 2018, President Donald Trump signed the “Right to Try Act,” a measure aimed at helping terminally ill patients access …

Uncategorized

Psilocybin for Treating Phantom Pain

Read this article at Psychedelic Science Review

Cognitive Enhancement / Mass / Microdosing / Psilocybin Chemistry

Microdosing – Unmet Need for Precise Dosing

Microdosing – Popular Trend Needing Greater Accuracy Recently, microdosing has been gaining popularity and attention.  The term “microdosing” is typically used to describe taking a small amount of a “psychedelic” …

Mushrooms / Psilocybin / Psilocybin Chemistry

COMPASS Pathways is NOT “Giving Mushrooms to Depressed Patients”

COMPASS pathways is not giving mushrooms to depressed patients. The New York Post published an article titled, “Startup plans to give mushrooms to depressed patients.”  The article is about COMPASS Pathways of London.  …

Mushrooms / Psilocybin / Research / Treatment

Psilocybin for Treating Violent Behavior

Psilocybin as a Means of Curbing Violent Behavior  ABSTRACT Within the last four years, two prominent psychology researchers published reports related to the effects of hallucinogens and their potential for …

Posts navigation

Older posts

Recent Posts

  • Nova Mentis Launches Entourage Effect Research
  • Graham Pechenik and Noah Potter discuss Psychedelic Patents
  • MindMed – Two Steps Closer to Next Generation Magic Mushroom Formulations
  • COMPASS Pathways’ $100+ Million Crystalline Form Patent
  • MagicMed – The First Psychedelic Patent Troll?

Recent Comments

  • Psilocybin Expert on Taking Pure Psilocybin is Different from Eating Magic Mushrooms
  • jim on Cannabis and Magic Mushrooms – A Near Perfect Analogy
  • jeff on China Enters Magic Mushroom Industry – Wuhan, MJMedTech, and M2BIO
  • jeff on Chemical & Engineering News Discusses Entourage Effect
  • jeff on Psilocybin Clinical Trials Approved by FDA

Archives

  • January 2021
  • November 2020
  • September 2020
  • July 2020
  • February 2020
  • January 2020
  • December 2019
  • August 2019
  • July 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • November 2017
  • October 2017

Categories

  • Aeruginascin
  • Anxiety
  • Business
  • Cognitive Enhancement
  • Decriminalization
  • Depression
  • Law
  • Legalization
  • Mass
  • Microdosing
  • Molecules vs. Mushrooms
  • Mushrooms
  • Patents
  • Psilocin
  • Psilocybin
  • Psilocybin Chemistry
  • Psilocybin Derivatives
  • Psilocybin Science
  • Research
  • State of the Art
  • Treatment
  • Uncategorized
  • Unmet Need
  • Wood Lover Paralysis

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org
Copyright © 2021 Psilocybin Technology – OnePress theme by FameThemes